AMRN Amarin Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: AMRN

Price (delayed)

$14.15

Market cap

$294.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.4

Enterprise value

$155.87M

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 26
Relative Valuation: Rel. Valuation: 24
Relative Profitability: Rel. Profitability: 38

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional ...

Highlights
AMRN's net income has soared by 74% YoY and by 19% from the previous quarter
The company's EPS has surged by 72% YoY and by 13% QoQ
AMRN's gross margin is down by 20% since the previous quarter but it is up by 12% year-on-year
Amarin's gross profit has decreased by 31% QoQ and by 4.9% YoY
The revenue is down by 15% year-on-year and by 14% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.amarincorp.com
Peers: ABBV ALKS TEVA AZN

Key stats

What are the main financial stats of AMRN

AMRN stock price

How has the Amarin stock price performed over time
Intraday
0.64%
1 week
-0.77%
1 month
-3.74%
1 year
-5.67%
YTD
1.4%
QTD
-11.23%

Financial performance

How have Amarin's revenue and profit performed over time
Revenue
$186.23M
Gross profit
$78.14M
Operating income
-$40.77M
Net income
-$27.12M
Gross margin
42%
Net margin
-14.6%
AMRN's net income has soared by 74% YoY and by 19% from the previous quarter
AMRN's net margin has surged by 69% year-on-year and by 6% since the previous quarter
AMRN's operating income has soared by 63% year-on-year and by 9% since the previous quarter
AMRN's operating margin has surged by 56% year-on-year but it is down by 6% since the previous quarter

Price vs fundamentals

How does AMRN's price correlate with its fundamentals

Growth

What is Amarin's growth rate over time

Valuation

What is Amarin stock price valuation
P/E
N/A
P/B
0.67
P/S
1.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.84
The company's EPS has surged by 72% YoY and by 13% QoQ
AMRN's P/B is 26% below its 5-year quarterly average of 0.9 and 4.3% below its last 4 quarters average of 0.7
The equity has declined by 4.6% year-on-year
The revenue is down by 15% year-on-year and by 14% since the previous quarter
The P/S is 5% more than the 5-year quarterly average of 1.5 and 5% more than the last 4 quarters average of 1.5

Efficiency

How efficient is Amarin business performance
AMRN's ROE has soared by 72% YoY and by 18% from the previous quarter
Amarin's ROA has soared by 72% YoY and by 18% from the previous quarter
The ROIC has soared by 71% YoY and by 16% QoQ
The company's return on sales has surged by 69% YoY and by 3.5% QoQ

Dividends

What is AMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMRN.

Financial health

How did Amarin financials performed over time
The current ratio has grown by 13% YoY and by 5% from the previous quarter
AMRN's total liabilities is down by 12% year-on-year and by 8% since the previous quarter
AMRN's debt is 99% smaller than its equity
Amarin's debt to equity has plunged by 50% YoY
AMRN's debt is down by 28% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.